Neville Rodie Shaw Inc Lowers stake in Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific (TMO) : Neville Rodie Shaw Inc reduced its stake in Thermo Fisher Scientific by 0.63% during the most recent quarter end. The investment management company now holds a total of 129,930 shares of Thermo Fisher Scientific which is valued at $18,884,026 after selling 824 shares in Thermo Fisher Scientific , the firm said in a disclosure report filed with the SEC on Apr 14, 2016.Thermo Fisher Scientific makes up approximately 2.26% of Neville Rodie Shaw Inc’s portfolio.

Thermo Fisher Scientific opened for trading at $145.42 and hit $146.6 on the upside on Monday, eventually ending the session at $146.47, with a gain of 0.78% or 1.13 points. The heightened volatility saw the trading volume jump to 9,07,628 shares. Company has a market cap of $58,040 M.

Other Hedge Funds, Including , Intermede Investment Partners Ltd boosted its stake in TMO in the latest quarter, The investment management firm added 56,931 additional shares and now holds a total of 212,409 shares of Thermo Fisher Scientific which is valued at $30,871,524. Thermo Fisher Scientific makes up approx 3.69% of Intermede Investment Partners Ltd’s portfolio.Central Trust Co boosted its stake in TMO in the latest quarter, The investment management firm added 4,239 additional shares and now holds a total of 22,043 shares of Thermo Fisher Scientific which is valued at $3,203,730. Thermo Fisher Scientific makes up approx 0.25% of Central Trust Co’s portfolio.Exxonmobil Investment Management Inc Tx boosted its stake in TMO in the latest quarter, The investment management firm added 7,025 additional shares and now holds a total of 96,480 shares of Thermo Fisher Scientific which is valued at $14,022,403. Thermo Fisher Scientific makes up approx 0.32% of Exxonmobil Investment Management Inc Tx’s portfolio.Chelsea Counsel Co reduced its stake in TMO by selling 4,110 shares or 7.73% in the most recent quarter. The Hedge Fund company now holds 49,073 shares of TMO which is valued at $6,951,681. Thermo Fisher Scientific makes up approx 2.01% of Chelsea Counsel Co’s portfolio.

On the company’s financial health, Thermo Fisher Scientific reported $2.12 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jan 28, 2016. Analyst had a consensus of $2.11. The company had revenue of $4652.50 million for the quarter, compared to analysts expectations of $4551.79 million. The company’s revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.99 EPS.

Many Wall Street Analysts have commented on Thermo Fisher Scientific. Company shares were Reiterated by Mizuho on Apr 4, 2016 to “Buy”, Firm has raised the Price Target to $ 160 from a previous price target of $150 .Company shares were Reiterated by Topeka Capital Markets on Mar 2, 2016 to “Buy”, Firm has raised the Price Target to $ 155 from a previous price target of $145 .

Thermo Fisher Scientific Inc. is a provider of analytical instruments equipment reagents and consumables software and services for research manufacturing analysis discovery and diagnostics. The company operates through four segments: Life Sciences Solutions provides reagents instruments and consumables used in biological and medical research discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments provides instruments consumables software and services that are used in the laboratory; Specialty Diagnostics offers diagnostic test kits reagents culture media instruments and associated products and Laboratory Products and Services offers self-manufactured and sourced products for the laboratory.

Leave a Reply

Thermo Fisher Scientific - Is it time to Sell?

Top Brokerage Firms are advising their investors on Thermo Fisher Scientific. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.